Loading...
Please wait, while we are loading the content...
Strategic R&D Investment Decisions in the Pharmaceutical Industry
| Content Provider | Semantic Scholar |
|---|---|
| Author | Rao, Anita |
| Copyright Year | 2017 |
| Abstract | Do pharmaceutical firms respond to the actions of their competitors in R&D, and how much? Answering this has implications on the impact of a faster FDA approval process - something pharmaceutical companies are pushing for. While a faster approval process leads to quicker realization of profits and more remaining time on the firm's patent, it also intensifies competition reducing per-firm profits. Which effect dominates depends on the degree of competition. To this end, I estimate a dynamic investment model using Phase-3 data. Solving the new equilibrium, I find an expedited process is beneficial only when competitors are far from launching. |
| File Format | PDF HTM / HTML |
| DOI | 10.2139/ssrn.2652755 |
| Alternate Webpage(s) | https://conference.nber.org/conf_papers/f83485.pdf |
| Alternate Webpage(s) | http://web-docs.stern.nyu.edu/marketing/S16Seminar/RaoAbstract.pdf |
| Alternate Webpage(s) | http://home.uchicago.edu/~anitarao/index_files/Pharmaceutical.pdf |
| Alternate Webpage(s) | https://doi.org/10.2139/ssrn.2652755 |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |